- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-mer
- Ligands
- 3 x NAG- NAG- BMA- MAN- NAG- NAG- BMA- FUC: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)][beta-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG-NAG.2: 3 residues within 4Å:- Chain B: N.149, S.151, W.152
1 PLIP interactions:1 interactions with chain B- Hydrophobic interactions: B:W.152
NAG-NAG.4: 3 residues within 4Å:- Chain A: N.149, S.151, W.152
1 PLIP interactions:1 interactions with chain A- Hydrophobic interactions: A:W.152
NAG-NAG.7: 3 residues within 4Å:- Chain C: N.149, S.151, W.152
No protein-ligand interaction detected (PLIP)- 1 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 28 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)(Non-covalent)
NAG.8: 1 residues within 4Å:- Chain A: N.603
Ligand excluded by PLIPNAG.9: 1 residues within 4Å:- Chain A: N.616
Ligand excluded by PLIPNAG.10: 1 residues within 4Å:- Chain A: N.657
Ligand excluded by PLIPNAG.11: 3 residues within 4Å:- Chain A: N.709, I.1130, G.1131
Ligand excluded by PLIPNAG.12: 4 residues within 4Å:- Chain A: N.331, P.579, Q.580, L.582
Ligand excluded by PLIPNAG.13: 3 residues within 4Å:- Chain A: E.340, N.343, A.344
Ligand excluded by PLIPNAG.14: 3 residues within 4Å:- Chain A: N.122, T.124, N.125
Ligand excluded by PLIPNAG.15: 2 residues within 4Å:- Chain A: Y.28, N.61
Ligand excluded by PLIPNAG.16: 2 residues within 4Å:- Chain A: N.164, N.165
Ligand excluded by PLIPNAG.17: 2 residues within 4Å:- Chain B: S.60
- Ligands: NAG.25
Ligand excluded by PLIPNAG.18: 1 residues within 4Å:- Chain B: N.603
Ligand excluded by PLIPNAG.19: 2 residues within 4Å:- Chain B: N.616, Q.644
Ligand excluded by PLIPNAG.20: 1 residues within 4Å:- Chain B: N.657
Ligand excluded by PLIPNAG.21: 2 residues within 4Å:- Chain B: N.709, N.710
Ligand excluded by PLIPNAG.22: 1 residues within 4Å:- Chain B: N.1074
Ligand excluded by PLIPNAG.23: 3 residues within 4Å:- Chain B: S.112, K.113, E.132
Ligand excluded by PLIPNAG.24: 5 residues within 4Å:- Chain B: N.122, T.124, N.125, S.155, F.157
Ligand excluded by PLIPNAG.25: 3 residues within 4Å:- Chain B: Y.28, N.61
- Ligands: NAG.17
Ligand excluded by PLIPNAG.26: 2 residues within 4Å:- Chain B: N.164, N.165
Ligand excluded by PLIPNAG.27: 3 residues within 4Å:- Chain B: K.558
- Chain C: G.283, T.284
Ligand excluded by PLIPNAG.28: 3 residues within 4Å:- Chain C: N.331, Q.580, L.582
Ligand excluded by PLIPNAG.29: 4 residues within 4Å:- Chain C: F.338, G.339, F.342, N.343
Ligand excluded by PLIPNAG.30: 3 residues within 4Å:- Chain C: N.616, T.618, Q.644
Ligand excluded by PLIPNAG.31: 1 residues within 4Å:- Chain C: N.657
Ligand excluded by PLIPNAG.32: 2 residues within 4Å:- Chain C: N.709, N.710
Ligand excluded by PLIPNAG.33: 3 residues within 4Å:- Chain C: A.713, K.1073, N.1074
Ligand excluded by PLIPNAG.34: 2 residues within 4Å:- Chain C: Y.28, N.61
Ligand excluded by PLIPNAG.35: 2 residues within 4Å:- Chain C: N.164, N.165
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Madan, B. et al., Antibody screening at reduced pH enables preferential selection of potently neutralizing antibodies targeting SARS-CoV-2. Aiche J (2021)
- Release Date
- 2022-05-25
- Peptides
- Spike glycoprotein: ABC
LP5 Fab Heavy Chain: DFH
LP5 Fab Light Chain: EGI - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
GF
IH
HE
JG
KI
L
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-mer
- Ligands
- 3 x NAG- NAG- BMA- MAN- NAG- NAG- BMA- FUC: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)][beta-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 28 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Madan, B. et al., Antibody screening at reduced pH enables preferential selection of potently neutralizing antibodies targeting SARS-CoV-2. Aiche J (2021)
- Release Date
- 2022-05-25
- Peptides
- Spike glycoprotein: ABC
LP5 Fab Heavy Chain: DFH
LP5 Fab Light Chain: EGI - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
GF
IH
HE
JG
KI
L